DOWNERS GROVE, Ill.--Vysis announced the availability of its first group of TelVysion DNA probes for the detection of genetic abnormalities involving telomeres for prenatal, congenital, and cancer research. The probes utilize Vysis's fluorescence in situ hybridization (FISH) technology to visually detect translocations associated with disease. The probes were developed in connection with a research and exclusive license agreement with the University of Chicago. The complete line of Vysis's TelVysion FISH probes will consist of 82 products, with 41 probes specific to telomeric regions of each human chromosome.
Vysis Introduces DNA Probes for Identifying Genetic Abnormalities
Dec 18, 1998